

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

Mouse Anti-CD3 Monoclonal Antibody, FITC Conjugated, Clone SK7

RRID:AB_400405

Type: Antibody

Proper Citation

BD Biosciences Cat# 349201, RRID:AB_400405

Antibody Information

URL: http://antibodyregistry.org/AB_400405

Proper Citation: BD Biosciences Cat# 349201, RRID:AB_400405

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Mouse Anti-CD3 Monoclonal Antibody, FITC Conjugated, Clone SK7

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone SK7

Antibody ID: AB_400405

Vendor: BD Biosciences

Catalog Number: 349201

Record Creation Time: 20250820T011910+0000

Record Last Update: 20250820T103639+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-CD3 Monoclonal Antibody, FITC Conjugated, Clone SK7.

No alerts have been found for Mouse Anti-CD3 Monoclonal Antibody, FITC Conjugated, Clone SK7.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kim WJ, et al. (2025) Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. *Cell*, 188(13), 3422.

Wang K, et al. (2025) Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia. *bioRxiv : the preprint server for biology*.

Lin SH, et al. (2025) Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. *Med (New York, N.Y.)*, 100752.

Barish ME, et al. (2025) Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety. *Cell reports. Medicine*, 6(8), 102302.

Ma R, et al. (2024) Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. *Cell reports. Medicine*, 5(7), 101628.

Montalban-Bravo G, et al. (2024) Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. *Cell reports. Medicine*, 5(6), 101585.

Kan WL, et al. (2023) Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia. *Cancer discovery*, 13(8), 1922.

Krivdova G, et al. (2022) Identification of the global miR-130a targetome reveals a role for TBL1XR1 in hematopoietic stem cell self-renewal and t(8;21) AML. *Cell reports*, 38(10), 110481.

Ganan-Gomez I, et al. (2022) Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes. *STAR protocols*, 3(4), 101764.

García-Prat L, et al. (2021) TFEB-mediated endolysosomal activity controls human hematopoietic stem cell fate. *Cell stem cell*, 28(10), 1838.

Khan H, et al. (2019) Metabolic Rewiring in Response to Biguanides Is Mediated by mROS/HIF-1a in Malignant Lymphocytes. *Cell reports*, 29(10), 3009.